Transcranial direct current stimulation for migrane-Reference-Cited by-同舟云学术

Transcranial direct current stimulation for migrane

Published:2024-05-01 Issue:3 Volume: Page:51-59
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Bordovsky S. P.¹^ORCID,Andreev S. S.²^ORCID,Zinchenko O. O.²^ORCID,Panina U. V.¹^ORCID,Kotenko V. D.¹^ORCID,Takhirov R. A.¹^ORCID,Potakhina A. E.³^ORCID,Shevtsova K. V.¹^ORCID

Affiliation:

1. Sechenov First Moscow State Medical University (Sechenov University)

2. HSE University

3. Pirogov Russian National Research Medical University

Abstract

Migraine is one of the most common primary headache disorders. Nowadays, there is an increase in the prevalence of migraine. It causes a significant reduction in the Quality of Life of those affected. There are two major approaches to treating migraines: attack management and prevention. The concept of primary prophylactic therapy of migraine has developed rapidly. In addition to standard medication, there are increasing data indicating the usefulness and feasibility of non-drug treatments, such as TES (transcranial electrical stimulation). Both cathodal and anodal stimulation have been shown to be effective in migraine treatment: after a course of TES, the number of days per month with headache decreased, the duration and intensity of migraine attacks decreased, and some studies reported a reduction in the number of medications used. O1/O2 (1–2 mA) for cathodal stimulation and F3/F4 (1–2 mA) for anodal stimulation were the most frequently stimulated cortical areas. The average duration of each session was 20 minutes. The length of TES sessions varied from study to study. TES has shown efficacy and safety in treating various forms of migraine. Using this non-invasive method to prevent attacks may be one of the directions for personalizing migraine treatment.

Publisher

Remedium, Ltd.

Reference34 articles.

1. Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19(2):109–117. https://doi.org/10.1038/s41582-022-00763-1. 2. Lew C, Punnapuzha S. Migraine Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK553159.

2. Tabeeva GR, Katsapava Z. Current concept of the pathophysiology of migraine and new targets for its therapy. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):143–152. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-143-152.

3. Sergeev AV, Tabeeva GR, Filatova EG, Amelin AV, Akhmadeeva LR, Lebedeva ER et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109–116. (In Russ.) https://doi.org/10.14412/2074-2711-2022-5-109-116.

4. Lanteri-Minet M, Goadsby PJ, Reuter U, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2021;92(5):466–472. https://doi.org/10.1136/jnnp-2020-324396.

5. Tabeeva GR. Problems in the selection of effective analgesics for migraine. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):109–116. (In Russ.) https://doi.org/10.14412/2074-2711-2023-5-109-116.